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Abstract
Background: The optimal extent of the prostate biopsy
remains controversial. There is a need to avoid detection
of insignificant cancer but not to miss significant and cur-
able tumors. In alternative treatments of prostate cancer,
repeated sextant biopsies are used to estimate the re-
sponse. The aim of this study was to investigate the reli-
ability of a repeated systematic sextant biopsy as the
standard biopsy technique in patients with significant
tumors which are being considered for curative treat-
ment. Methods: Systematic sextant biopsy was per-
formed in vitro in 92 radical prostatectomy specimens.
Of these patients, 81 (88.0%) had palpable lesions. Re-
sults: Of the 92 investigated patients, 70 (76.1%) had
potentially curable pT2-3pN0 prostate cancers. In these
patients, the cancer was detected only in 72.9% of cases
by a repeated in vitro biopsy. In the pT2 tumors, there
was a detection rate of only 66.7%. Conclusions: This
study underlines the fact that a considerable number of
significant and potentially curable tumors remain unde-
tected by the conventional sextant biopsy. A negative
sextant biopsy does not rule out significant prostate can-
cer.
Copyright © 2000 S. Karger AG, Basel
Introduction
In the pre-prostate-specific antigen (PSA) era, prostate
cancer (CaP) was generally detected when a suspicious
finding in the digital rectal examination (DRE) led to a
finger-guided biopsy of the prostate. The widespread use
of PSA screening increased the incidence of CaP dramati-
cally [1]. As a consequence, the rising trend in CaP mor-
tality was slightly reversed [1]. Hodge et al. [2] were the
first to suggest ultrasound-guided transrectal sextant biop-
sy for the diagnosis of the palpably abnormal prostate.
Although this technique is considered by many to be the
standard procedure [3, 4], there is an ongoing controversy
on the optimal extent of the prostate biopsy. The objec-
tive of this study was therefore to investigate the reliabili-
ty of a repeated systematic sextant biopsy as the standard
biopsy technique in patients with significant tumors
which are considered curable.
pT2pN0M0
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Table 1. Tumor classification and number
of positive biopsies Stage n At least one
positive biopsy
No positive
biopsy core
Average number
of positive biopsy
cores (range)
36 24 (66.7%) 12 1.3 (0–6)
pT3pN0M0 34 27 (79.4%) 7 2.2 (0–6)
pT4apN0M0 13 13 (100%) 0 3.7 (1–6)
pT2-4pN1M0 9 8 (88.9%) 1 2.9 (0–5)
Total 92 72 20 2.2 (0–6)
Materials and Methods
Ninety-two patients with pathohistologically-proven CaP were
admitted to the study. Prostate specimens obtained by radical prosta-
tectomy were used to simulate in vitro a systematic random biopsy.
The patients were aged between 48 and 76 years (mean 58.2). The
PSA value ranged between 0.2 and 149 ng/ml (mean 15.7). All
patients were judged to have a clinically localized cancer. Eleven
patients had only PSA-diagnosed tumors (cT1c), 81 patients had
clinically palpable and localized CaP without distant metastases and
prior therapy. Patients with neoadjuvant hormonal treatment were
excluded from this study. Patients underwent clinical staging evalua-
tion consisting of physical examination with DRE, chest X-ray, bone
scan, transrectal and abdominal ultrasound as well as measurement
of serum PSA levels prior to DRE and radical prostatectomy. After
radical prostatectomy a randomized systematic biopsy from the radi-
cal prostatectomy specimen was performed using a Biopty-Gun®
with an 18-gauge needle in the theater. In all prostates, 6 biopsy cores
were obtained. The 6 biopsy sites were located at the apex, middle
and the basis of the prostate bilaterally, as described by Hodge et al.
[2] (fig. 1). The biopsy cores were then fixed in formalin. The follow-
ing histological examination of the radical prostatectomy specimen
was done according to a discretely modified McNeal technique [5].
The staging procedure was carried out using the TNM classification
of 1997. The mean number of positive biopsies obtained in patients
with a certain tumor stage was compared using the Mann-Whitney
test.
Results
The results of the histological examination of the speci-
mens obtained after radical prostatectomy and the results
of the in vitro biopsies are shown in table 1 and 2. The
most common tumor classification was pT2pN0 (n = 36,
39.1%), followed by pT3pN0 (n = 34, 37.0%) and
pT4apN0 (n = 13, 14.1%). Lymph node involvement was
found in 9 patients (9.8%). Of the 92 patients enrolled in
this study, no cancer was found in all 6 biopsy cores in 20
cases (21.7%), 72 (78.3%) had at least 1 positive postoper-
ative biopsy core. Among the 36 patients with pT2pN0
Table 2. Comparison of the number of positive biopsies according to
the TNM classification of the tumors
Compared tumor classifications p value (Mann-Whitney test)
pT2pN0M0 vs. pT3pN0M0 0.015
pT2pN0M0 vs. pT4apN0M0 0.000
pT2pN0M0 vs. pT2-4pN1M0 0.018
pT3pN0M0 vs. pT4apN0M0 0.018
pT3pN0M0 vs. pT2-4pN1M0 0.29
Fig. 1. Location of the in vitro biopsy sites after radical prostatecto-
my.
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tumor, cancer was detected by in vitro random biopsy in
24 cases (66.7%), among the 34 patients with stage
pT3pN0, cancer was detected in 27 cases (79.4%). All but
1 of the 22 patients with stage pT4apN0 or pT2-4pN1 had
at least 1 positive biopsy core (table 1). Considering the
potentially curable tumor stages pT2-3pN0 together (n =
70), repeated sextant biopsies were negative in 19 cases
(27.1%). The number of positive biopsy cores of the
repeated biopsy is given in table 1.
Discussion
The results of this study demonstrate that random sex-
tant biopsy of the prostate obtained postoperatively from
radical prostatectomy specimens leaves a considerable
portion (21.7%) of clinically significant CaPs undetected.
Only repeat biopsies in the incurable tumor stages pT4 or
pN1 were nearly uniformally positive. In patients with a
pT2 tumor, every third tumor remains undetected by
repeat biopsy. In a study of 193 patients with T1c tumors
by Epstein et al. [6] in 1997, 31.1% negative repeat biop-
sies were found. This is no different from the pT2 tumors
in our study. Epstein et al. concluded that tumors which
are negative on repeat sextant biopsy do not necessarily
represent insignificant cancer. Rabbani et al. [7] reported
a 77% detection rate of repeat sextant biopsy in bioptical-
ly-proven organ-confined CaPs and highlighted the con-
siderable sampling error in significant CaPs. Considering
corresponding histologically-confined tumor-positive ar-
eas in radical prostatectomy specimens, in a recent study
[3] even less than 50% of the lesions were identified by
sextant biopsy. All comparable studies [3, 7, 8], including
the present one, demonstrate a remarkably poor redetec-
tion rate of repeat sextant biopsy, especially in potentially
curable organ-confined cancers. These data have implica-
tions for the evaluation of a negative sextant biopsy in
men suspected of having CaP. All these patients should be
considered candidates for a second sextant biopsy after an
interval of some weeks. As demonstrated by Häggman et
al. [8] the detection rate could be improved by taking
more biopsies. Using 10 core biopsies, they found in 60
patients a detection rate of 92% after radical prostatec-
tomy.
Besides these considerations involving the detection of
significant and potentially curable CaP, the above-men-
tioned biopsy data raise questions about the clinical value
of repeat biopsies in the monitoring of alternatively
treated CaP patients undergoing a prostate-sparing proce-
dure like radiotherapy, high intensive focused ultrasound
(HIFU) or cryoablation. Repeat sextant biopsies have
been used as response criteria in the evaluation of the effi-
cacy of cryoablation of prostate [9] and HIFU [10–12].
Albert et al. [10, 11] defined complete response after
HIFU for organ-confined CaP as negative repeated sex-
tant biopsies and reported complete response rates of each
61% [10, 11]. In the light of the rate of negative biopsies
obtained in pT2 tumors in the present series, one can esti-
mate that the real rate of complete destruction of cancer
by HIFU is probably less than 50%, especially considering
the difficulty in identifying small residual cancer nests
after extensive destruction of the prostate gland. The
response criteria established by Thüroff and Chaussy [12]
appear even more problematic. These authors used repeat
prostate biopsy not only to define complete remission
after HIFU but even partial remission, stable and progres-
sive disease, using the number of positive posttreatment
biopsies, compared with the pretreatment biopsy. These
criteria seem questionable and hardly represent the real
status of cancer after HIFU. Repeat biopsies after pros-
tate-sparing treatment for CaP are probably only suitable
for the documentation of treatment failure. Durable com-
plete remission after these treatment modalities should be
defined using PSA nadir and PSA velocity rather than
repeat sextant biopsies.
Conclusions
The present study provides further evidence for the rel-
atively low detection rate of organ-confined prostate can-
cer by conventional sextant biopsy and underlines the
need for alternative strategies in the identification of
patients who are suitable for curative treatment of CaP.
On the other hand, the low detection rate of carcinoma of
the prostate in locally confined carcinoma challenges the
response criteria based on a repeat sextant biopsy in the
evaluation of the efficacy of alternative prostate-sparing
treatment modalities for CaP.
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